AU · rank #1 · 2026-10-20
SNT
GPW · PLN · $751M (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.741 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$2.35 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $373.00 | +8.9% |
| Momentum acceleration 3-month minus 12-month momentum. | -17.98% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | — |
| Gross margin TTM | +35.1% |
| 52w high | $398.40 |
| Market cap (USD) | $751M |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Synektik S.A. distributes and services da Vinci robotic-surgery systems across Central/Eastern Europe, alongside medical imaging, nuclear medicine and radiopharma operations.
Rationale
The quant setup looks supported by 30-day EPS upgrades, 100% revision agreement, and a still-positive ~9% analyst upside after record Q3 FY2025/26 revenue/EBITDA growth and strong cash generation.
Material risks
- 1The core moat is Intuitive Surgical’s exclusive distribution rights, so any loss of that sole-supplier position or a shift to direct sales would directly break the thesis.
- 2Order visibility has weakened, with Q4 orders down sharply and backlog falling to PLN 43.3 million from PLN 75.9 million, making near-term revenue conversion more dependent on hospital procurement timing.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.